acute coronary syndrome
Acute coronary syndrome market to grow to over $12 billion by 2022
August 15, 2016Research and Development, Sales and Marketing GlobalData, acute coronary syndrome
The acute coronary syndrome (ACS) market is forecast to rise from $7.8 billion in 2015 to $12.1 billion by 2022 …
AstraZeneca’s troubled Brilinta gets welcome lift
January 14, 2015Sales and Marketing AstraZeneca, Brilinta, FDA, US Department of Justice, acute coronary syndrome, ticagrelor
AstraZeneca has reported positive primary endpoint results for its anti-clogging drug Brilinta to treat patients who have had a heart …
Merck suffers late-stage blow to vorapaxar
January 18, 2011Research and Development ACS, Merck & Co, acute coronary syndrome, anticoagulant, heart attack, peripheral arterial disease, stroke, vorapaxar
An increased risk of bleeding caused by pipeline drug vorapaxar has dealt Merck a major blow.The Data and Safety Monitoring …
FDA delays approval of AstraZeneca’s Brilinta
December 20, 2010Research and Development, Sales and Marketing AZ, AstraZeneca, Brilinta, Brilique, acute coronary syndrome
US regulators have delayed approving AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor) because their want more information about a crucial clinical trial. …
Latest content
Ofichem acquires US drug substance CDMO Kinentia
October 14, 2026
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
October 13, 2026
Tridem begins phase Ib trial of Parkinson’s disease vaccine
October 13, 2026
